SphingoTec GmbH

SphingoTec Announces Management Changes

New Formula Leverages Proenkephalin A 119-159 (penKid) for Improved GFR Estimation in Steady-State and Critically Ill Patients

International Experts Highlight Demand for Diagnostic Innovations as PenKid’s Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools

Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid

SphingoTec’s Innovative IVD Product sphingotest® penKid® Receives First IVDR Certificate

ADQI Group Recognizes PenKid as Relevant Functional Biomarker for Sepsis-Associated Acute Kidney Injury